Related coverage linked through entity extraction aliases.
Feb 19, 2026
A UC Santa Barbara research team has developed a technique for efficiently synthesizing non-natural amino acids and applying them to peptide construction, published in the Journal of the American Chemical Society.
Feb 19, 2026
Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.
Feb 17, 2026
Sana Biotechnology appointed Brian Piper as Executive Vice President and Chief Financial Officer on February 17, 2026. Piper brings over 25 years of biopharmaceutical financial expertise to the cell and gene therapy company.
Feb 17, 2026
Portal Diabetes, Inc. announced FDA Breakthrough Device Designation for its implantable insulin pump system and initiated a Phase 1 study of its proprietary temperature-stable insulin for type 1 diabetes treatment.
Feb 15, 2026
MannKind Corporation has enrolled the first pediatric patient in its INHALE-1ST trial evaluating Afrezza inhaled insulin in children with type 1 diabetes. The FDA is reviewing a supplemental Biologics License Application with a decision expected by May 29, 2026.
